In this issue of *Seminars in Pediatric Infectious Diseases*, Guest Editor Dr. Heidi Schwarzwald brings to our attention a matter that often is overlooked by physicians who have had the privilege of treating patients in developed countries: diseases once considered conquered or not endemic in developed countries now are appearing at a rate that once was considered unthinkable. Although our complacency in the developed world concerning infectious diseases of other locales was shattered initially with outbreaks of acquired immunodeficiency disease, the epidemic in 2003 of severe acute respiratory syndrome (SARS) highlighted the need to be vigilant concerning transmission of infectious diseases that many physicians seldom have encountered in the recent past.

Many factors have contributed to the emergence in developed countries of rare diseases or those that have become almost nonexistent since the development of vaccines and other treatment modalities. Among these factors are the mobility of today's society and the frequency of international travel, as well as the short length of time required to travel far distances---durations of time often shorter than those required for the incubation of diseases. Other factors pertinent to this issue of *Seminars* include the increased immigration into this country, some of which is uncontrolled and thus often accompanied by failure to obtain appropriate medical care and immunizations before or after arrival, and international adoptions, which may involve treating children from areas of the world with diseases not found commonly in the United States. Each of these factors contributes to the increase in the number of infectious diseases and, in turn, poses an additional challenge to the clinician to expand his or her expertise in the area of differential diagnoses.

The Guest Editor, Dr. Heidi Schwarzwald, opens the discussion of these timely topics by focusing on illnesses that are found among children who immigrate to the United States. The number of these children exceeded 186,000 in 2002 alone. The number of children entering the country without appropriate screening rose, and the illegal immigration also continues to increase. Dr. Schwarzwald focuses on the common infectious diseases that are encountered, among them intestinal parasites, tuberculosis, hepatitis B and C, malaria, human immunodeficiency virus (HIV), measles, and SARS. She then explains aspects of the medical evaluation of this particular population of patients with regard to obtaining the available history of the child on arrival in the United States, recognizing that the type and validity of the histories will vary; providing immunizations; assessing the child's growth and development, noting that a delay in growth is not an uncommon finding; and obtaining appropriate laboratory examinations. In closing, she emphasizes that because these children are at high risk for having many infectious diseases, some of them seldom seen in this country, the burden of screening for various diseases and of having a high index of suspicion for unusual infectious agents lies with the pediatrician and other healthcare providers.

Drs. Miguel Cashat-Cruz, José Juan Morales-Aguirre, and Mónica Mendoza-Azpiri address the main cause of morbidity worldwide, acute respiratory infections (ARIs), as it affects children in developing countries. These authors first provide an overview of the etiology of pneumonia caused by *Haemophilus influenzae* and *Streptococcus pneumoniae* or associated with various viral and opportunistic infections. After describing specific aspects of diagnosing pneumonia in children in developing countries, the authors address the distressing mortality rates, noting that more than 10 million children younger than the age of 5 years died in 2000, most of them living in poor countries and dying from preventable causes. Children who died from ARIs accounted for an estimated 1.9 million of these deaths. Although most of the deaths occurred in sub-Saharan Africa and Southeast Asia, the poorer countries in the Americas also have been hard-hit, with 100,000 deaths occurring annually since 1980 in children younger than the age of 1 year being attributed to ARIs. Prevention, primarily through immunizations, vitamin and micronutrient supplements, and medical education, are addressed. The authors emphasize that concerted support efforts from industrialized countries are need to develop direct strategies to improve the general conditions of developing countries, which in turn would translate into improved healthcare outcomes.

Tuberculosis has been a recognized infectious disease for hundreds of years. Despite the progress that has been made in treating it, an enormous challenge remains in numerous areas. In the second article of this series, Drs. Jeffrey Starke and Anna M. Mandalakas point out that the emphasis in current guidelines for treating and controlling tuberculosis is placed on adult cases, with only cursory attention usually given to childhood tuberculosis. These authors address this discrepancy by noting the numerous reasons why estimating the burden of tuberculosis in children is challenging and the important differences that exist in the epidemiology of childhood tuberculosis in industrialized countries compared with those of low- or middle-income countries. After explaining the means of transmission, the authors turn the focus of their discussion to the disease itself. They review the concerns of pathology in children and clinical presentation of childhood tuberculosis and give particular attention to the specific characteristics of intrathoracic tuberculosis and extrathoracic tuberculosis. In the discussion of the diagnostic concerns, the authors discuss the use of tuberculin skin test and laboratory diagnosis using staining and microscopic examination, culture, or other newer diagnostic modalities. A discussion of therapeutic aspects includes the effects of exposure and efficacy of various therapies for latent tuberculosis infection and for tuberculosis. The means of controlling and preventing tuberculosis, Bacille Calmette-Guerin vaccines and involvement of public health programs, are addressed in the final portion of the article. The authors conclude by emphasizing that the 90 percent of the world's children born into resource-poor countries should have equal access to directly observed therapy strategies.

Malaria also has a significant impact on the pediatric populations worldwide, accounting for more than a million pediatric deaths each year. The most significant parasitic infection worldwide, it is associated strongly with poverty and imposes tremendous challenges to developing countries. Drs. Andrea P. Summer, William M. Stauffer, and Philip R. Fischer describe the impact of pediatric malaria in the developing world. After describing the four parasitic species of the genus *Plasmodium* that cause malaria, these authors discuss the various control measures that target the complex life cycle of the mosquito and barriers to prevention of the diseases. They then explain the clinical features, which are notoriously nonspecific particularly in children; specific concerns related to nonfalciparum malaria and to falciparum malaria; and the effects of congenital malaria. A brief discussion of diagnostic tests is followed by a description of the various therapeutic options, which depend on the infecting species, severity of disease, resistance patterns, and costs and availability of medications and resources. Practical considerations of dealing with malaria involve diagnosis and treatment, both of which receive substantial attention.

Another major contributor to the alarming mortality rate of children in developing countries is human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Since 1981, when the first cases of AIDS were diagnosed, approximately 4 million children have died of the disease. Drs. Gabriel Misango Anabwani, Elias Abebe Woldetsadik, and Mark W. Kline discuss the progress that is being made using antiretroviral drugs in African countries to treat children with HIV. After providing a review of the epidemiology of HIV worldwide, the authors explain the clinical manifestations and laboratory diagnosis of pediatric HIV. They then describe the various responses by the United Nations and other groups to the epidemic of HIV/AIDs in Africa. One important advance has been the movement to start 3,000,000 Africans on highly active antiretroviral therapy (HAART) by the year 2005. The ongoing Botswana-Baylor Antiretroviral Assessment 02 (BANA 02) trial at the new Botswana-Baylor Children's Clinical Centre of Excellence provides evidence that it may contribute to the management of HIV-infected children worldwide. The authors then focus on specific antiretroviral agents currently used to treat pediatric HIV infections, namely the nucleoside reverse transcriptase inhibitors, the nonnucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, and generic or copy antiretroviral drugs. They describe the various drugs and their mechanisms of action, as well as their indications for use in pediatric HIV. The last portion of the article deals with the special considerations of using antiretroviral therapy in African countries, which include cost, availability, sustainability, and the balance between the current ideal and what may be adequate. The issues affecting adherence and the considerations for stopping therapy also are explained.

Despite tremendous advances that have been made in treating the various causes of diarrhea and the decline since 1980 in diarrhea-associated deaths, diarrhea continues to be a significant cause of morbidity and mortality worldwide. During the 1990s, an estimated 1.4 billion episodes of diarrhea occurred annually among children aged 5 years of age and younger. Drs. Miguel O'Ryan, Valeria Prado, and Larry K. Pickering describe the impact that acute diarrhea has on children worldwide, especially among those living in socioeconomically underdeveloped areas. They then address the relevant pathogens responsible for diarrhea, looking at individual enteric viruses, bacterial pathogens, and parasites. Clinical considerations and aspects of establishing the diagnosis that they address include the common definition of diarrhea, namely three or more stools during a 24-hour period, and extenuating circumstances that may alter that definition. The importance of establishing the diagnosis promptly to initiate appropriate care and of assessing the characteristics of the stools in determining the potential causative pathogens are emphasized. In the section on treatment modalities, the authors discuss the initial therapeutic interventions that are critical, as well as the various antimicrobial agents that are available for select bacterial and protozoal pathogens. They then describe the important considerations to be entertained with regard to the rising number of antibiotic-resistant bacteria, with a focus on *Shigella* spp., *Campylobacter jejuni*, *Campylobacter coli*, *Salmonella* spp., and shiga-toxin-producing *Escherichia coli*. Obviously, prevention of diarrhea is the most important aspect, and the authors explain techniques for the prevention of diarrheal disease through general public health and personal measures.

Dr. Schwarzwald is to be commended for her thoughtful selection of diseases that affect this population and for her selection of the appropriate authors to address each subject. All pediatricians and healthcare providers should become familiar with the treatment of immigrant children, and we are grateful to Dr. Schwarzwald for highlighting this responsibility and to the authors for sharing their expertise.

The Case Report is provided by Dr. Morven Edwards, Case Studies Editor. Authors Drs. Susan H. Wootton and Coburn H. Allen describe a 17-day-old infant who presented with fever and fussiness, as well as several days of congestion, rhinorrhea, and decreased oral intake. He also had a mottled appearance and white patches consistent with oral thrush in his oral mucosa. Given the details of the clinical examination and laboratory results, the question posed by the authors is "What causative organism would you consider?" The answer is found in the Denouement.

The Special Article continues our series on emerging or re-emerging infectious diseases with a review of the literature on gnathostomiasis. Dr. B. Lee Ligon presents the causes and epidemiology, diagnosis, and treatment of this rare disease, the cause of which has become endemic in numerous parts of the world.

The Biography is another in the series of biographies authored by individuals who knew the subjects personally. For this issue, we have a biography of Alfred Fabian Hess, authored by Dr. Murray H. Bass and published in 1957. We are grateful for the opportunity to bring these biographies, now almost a half century old, to the attention of a new audience.

On behalf of the editorial board, I thank the Guest Editor and each of the authors for their contributions to this important issue updating us on new concerns to be addressed in treating infectious diseases.
